ACDE - Antiresorptive Medications and MRONJ
This presentation provides an overview of Osteonecrosis of the Jaw (ONJ) and Medication-Related Osteonecrosis of the Jaw (MRONJ), focusing on understanding its types, definitions, causes, and management strategies. Participants will learn to identify and describe the three primary types of ONJ and the core elements that define MRONJ. Dr. Beals will cover the indications for antiresorptive medications, exploring the mechanisms of action for drugs like Denosumab and Bisphosphonates, and detailing both anabolic and anti-catabolic medication categories.
Additionally, the presentation will cover the pathophysiology, stages, and predisposing factors of MRONJ, providing a solid foundation for understanding its progression and impact. It will also address treatment goals, the American Association of Oral and Maxillofacial Surgeons (AAOMS) guidelines, and local wound care practices that promote healing.
Participants will examine the '4 Ds' of antiresorptive therapy, the delayed dosing protocol, and specialized decision-making tools, such as the extraction and MRONJ decision trees for Complex Dental Management and Assessment (CDMA) cases. Through these elements, the presentation aims to equip learners with practical strategies and evidence-based approaches for managing MRONJ in clinical settings.
Course Objectives:
At the conclusion of this course, participants will:
- Identify and describe Osteonecrosis of the Jaw (ONJ) and Medication-Related ONJ (MRONJ)
- Explain the mechanisms of action and therapeutic uses of medication involved in managing Osteonecrosis of the Jaw, ONJ, including antieresorptive and anabolic agents
- Discuss antiresorptive therapy and its guidelines
- Recognize predisposing factors and treatment goals in MRONJ
